Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Buy
71
CPIX Quote, Financials, Valuation and Earnings
Last price:
$2.39
Seasonality move
:
-3.69%
Day range:
$2.17 - $2.35
52-week range:
$1.04 - $3.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.86x
P/B ratio:
1.28x
Volume:
138.6K
Avg. volume:
3.7M
1-year change:
29.31%
Market cap:
$31.6M
Revenue:
$39.6M
EPS (TTM):
-$0.77
Analysts' Opinion
-
Consensus RatingCumberland Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Cumberland Pharmaceuticals has an estimated upside of 277.78% from its current price of $2.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.25.
Fair Value
-
According to the consensus of 0 analysts, Cumberland Pharmaceuticals has 277.78% upside to fair value with a price target of -- per share.
CPIX vs. S&P 500
-
Over the past 5 trading days, Cumberland Pharmaceuticals has overperformed the S&P 500 by 4.32% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cumberland Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cumberland Pharmaceuticals revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Cumberland Pharmaceuticals reported revenues of $9.1M.
Earnings Growth
-
Cumberland Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cumberland Pharmaceuticals reported earnings per share of -$0.11.
Enterprise value:
29.9M
EV / Invested capital:
0.74x
Price / LTM sales:
0.86x
EV / EBIT:
--
EV / Revenue:
0.81x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-17.43x
Price / Operating cash flow:
4.53x
Enterprise value / EBITDA:
16.53x
Gross Profit (TTM):
$30.6M
Return On Assets:
-13.38%
Net Income Margin (TTM):
-29.55%
Return On Equity:
-38.11%
Return On Invested Capital:
-25.1%
Operating Margin:
-18.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $41.2M | $39.3M | $36.8M | $10.1M | $9.1M | |
| Gross Profit | $31.4M | $32.1M | $30.6M | $8.3M | $7.8M | |
| Operating Income | -$7.8M | -$5.7M | -$10.8M | -$1.9M | -$1.7M | |
| EBITDA | -$1.2M | $3.2M | -$1.4M | $540.6K | $13.1K | |
| Diluted EPS | -$0.47 | -$0.17 | -$0.77 | -$0.07 | -$0.11 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $48.9M | $47.2M | $49.2M | $41.8M | $35.2M | |
| Total Assets | $96M | $87.6M | $90.8M | $87.8M | $76.7M | |
| Current Liabilities | $23.9M | $17.9M | $25.3M | $27.3M | $31.1M | |
| Total Liabilities | $48.2M | $40.9M | $52.3M | $52.1M | $52.3M | |
| Total Equity | $47.8M | $46.6M | $38.5M | $35.7M | $24.5M | |
| Total Debt | $17M | $15M | $17.7M | $12.9M | $16.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $6.8M | $8.7M | -$1.5M | $1.2M | $475.5K | |
| Cash From Investing | -$13.1M | -$1M | $345.3K | -$95.1K | $189.6K | |
| Cash From Financing | -$16.3K | -$8.7M | $88.2K | -$882.6K | -$536.8K | |
| Free Cash Flow | $6.3M | $6.7M | -$1.7M | $1.1M | $427.6K | |
CPIX
Sector
Market Cap
$31.6M
$45.6M
Price % of 52-Week High
73.77%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
0.45%
-0.74%
1-Year Price Total Return
29.31%
-31.35%
Beta (5-Year)
0.299
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.25
200-day SMA
Buy
Level
$1.48
Bollinger Bands (100)
Buy
Level
1.05 - 1.69
Chaikin Money Flow
Buy
Level
32.6M
20-day SMA
Buy
Level
$1.76
Relative Strength Index (RSI14)
Buy
Level
66.26
ADX Line
Sell
Level
15.63
Williams %R
Neutral
Level
-40.8163
50-day SMA
Buy
Level
$1.42
MACD (12, 26)
Buy
Level
0.29
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
303.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.3601)
Sell
CA Score
(Annual)
Level (-1.1422)
Buy
Beneish M-Score
(Annual)
Level (-3.4781)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.6031)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Stock Forecast FAQ
In the current month, CPIX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CPIX average analyst price target in the past 3 months is --.
-
Where Will Cumberland Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cumberland Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Cumberland Pharmaceuticals?
Analysts are divided on their view about Cumberland Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cumberland Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Cumberland Pharmaceuticals's Price Target?
The price target for Cumberland Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CPIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cumberland Pharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CPIX?
You can purchase shares of Cumberland Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cumberland Pharmaceuticals shares.
-
What Is The Cumberland Pharmaceuticals Share Price Today?
Cumberland Pharmaceuticals was last trading at $2.39 per share. This represents the most recent stock quote for Cumberland Pharmaceuticals. Yesterday, Cumberland Pharmaceuticals closed at $2.25 per share.
-
How To Buy Cumberland Pharmaceuticals Stock Online?
In order to purchase Cumberland Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 0.85% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.91% over the past day.
